David Del Bourgo

David Del Bourgo serves as the CEO of WhiteLab Genomics, a pioneering company at the forefront of genomic research and synthetic biology. With his visionary approach to the application of artificial intelligence in life sciences, Del Bourgo has been instrumental in advancing the company's mission to harness cutting-edge technology for the development of novel therapeutic solutions.

Under Del Bourgo's leadership, WhiteLab Genomics has achieved remarkable milestones, including the development of advanced AI-driven platforms that enable precise genomic modifications and predictive modeling of genetic outcomes. These innovations have not only enhanced the efficiency of research and development processes but also paved the way for personalized medicine approaches, offering hope for treatments tailored to individual genetic profiles.

Del Bourgo's strategic vision extends to fostering collaborations with academic institutions, pharmaceutical companies, and research organizations worldwide. His efforts have positioned WhiteLab Genomics as a key player in the global biotech ecosystem, driving forward initiatives that address some of our most challenging health issues. A passionate advocate for the ethical application of biotechnology, Del Bourgo is also actively involved in discussions on bioethics and regulatory standards.

Previous to founding WhiteLab Genomics, Del Bourgo led commercial operations, marketing, applications, internal services and customer support teams at genomic biotech and medtech companies. He also led both organic and external growth efforts companies in the medical imaging field and management consulting strategic due-diligences for private equity funds and corporate strategies in France and Europe. His career started at GE Healthcare where he spent seven years in engineering and marketing positions, principally on cardiovascular applications, both in x-ray and nuclear imaging modalities.

Del Bourgo holds an MBA from the University of Chicago Booth School of Business and two Masters of Science degrees in biomedical engineering, from Tel Aviv University and Université de Technologie de Compiègne.